|
|
|
| Customized mRNA-LNP Solutions | With a combined 20-year track record in the manufacturing of lipids, LNP, and mRNA, MilliporeSigma offers customizable mRNA-LNP CDMO services to meet your unique needs from pre-clinical to commercialization. Select integrated services from drug substance to Fill & Finish or individual components tailored to your project. Download the infographic to learn more! |
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | During our hour-long conversation, Sagaert and I covered a lot of ground on the current state of the industry. But given his background in quality, it shouldn’t come as a surprise that our conversation ultimately gravitated back to some of the biggest questions we currently have and need to answer about our product’s structure and function — and how to adequately demonstrate this critical knowledge to regulators. |
|
|
|
By Tyler Menichiello, contributing editor | Heidi Zhang, Ph.D., explains Tune Therapeutics' epigenetic approach to gene therapy and how the company is preparing its lead candidate for the clinic, as well as it's modular approach to automation. |
|
|
|
By C. Schoellhammer and P. Leclair, DeciBio Consulting | The oligonucleotides sector is quickly evolving and seeing more industry partnerships than ever before. We caught up with DeciBio's Carl Schoellhammer and Phillip Leclair for their analysis. |
|
|
|
mRNA product storage can be challenging due to extremely low temperature requirements. Here, Joseph Barberio of Strand Therapeutics and Christian Moreno of Nutcracker Therapeutics share their take on existing cold chain challenges. |
|
|
|
| The Future Of mRNA: Four Key Focuses For Industry | Article | Roche CustomBiotech | Compared to traditional protein-based therapies, mRNA drugs exhibit unique pharmacokinetic profiles and can be rapidly developed, making overcoming their challenges critical for the industry. |
|
|
|
|
|
|
|
|
.png){kind=logo}
